A recent letter in Leukemia1 reported the detection of the JAK2 V617F mutation at very low levels in peripheral blood of healthy donors. This finding is consistent with our own data generated using TaqMan (fluorescence-based real-time PCR) and minor groove binding probes designed for the quantitative determination of DNA copy number of JAK2 V617F.2
Apart from not using a plasmid standard curve containing the mutant allele to determine absolute copy number of JAK2 V617F, the characteristics of the previously reported assay appear very similar to our own.2 We found that our assay, which does not employ locked nucleotide technology, exhibited good reproducibility, efficiency and the correlation coefficient of the standard curve averaged 0.97. The assay showed 100% concordance with sequence-based typing (SBT) for detecting the presence of the mutation in samples with greater than 1000 copies (n=14), and detected low levels of the mutation in three samples that showed no mutation by SBT. We also detected the presence of the mutation to less then 0.05% clinical dilution (30 copies), with a linear range extending from 10 and 300 000 copies per reaction (Figure 1). By combining this assay with another TaqMan assay for determining cell copy number,3 we have been able to determine the average number of JAK2 V617F mutant copies per cell and per 20 ng of DNA in absolute terms from granulocyte fractions (Figure 2). Quantitative determination of JAK2 V617F by either means was extremely low among healthy controls (n=18), and we assumed this to represent non-specific amplification of the wild-type allele, as shown in Figure 1. Among patients presenting with suspected myeloproliferative disorders (n=131) some values were extremely high and included six measures greater than an average of 2.5 copies per cell from individuals. Although the veracity of this finding should be confirmed by an alternative approach, these data suggest that disease evolution may involve further gene duplication associated with genetic instability. Our data contribute to on-going questions regarding the interpretation of variations in JAK2 V617F copy number at the cell population level. Levels of mutation that are significantly above those seen in healthy controls are clearly of clinical relevance, but beyond providing an accurate measure of clonal proliferation, the potential contribution of this measure to inform clinical management remains to be demonstrated.
References
Sidon P, EL Housni H, Dessars B, Heimann L . The JAK2 V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006 [E-pub ahead of print] doi:10.1038/sj.leu.2404292.
Hammond E, Shaw K, Carnley B, P'ng S, James I, Herrmann R . Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagnostics (in press).
Hammond EL, Sayer D, Nolan D, Walker U, deRonde A, Montaner J et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; 27: 97–110.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hammond, E., Shaw, K. & Herrmann, R. The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders. Leukemia 21, 815–816 (2007). https://doi.org/10.1038/sj.leu.2404567
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404567